Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22570461 | 0.81 | ALDH1A1 (0.68) | ALDH1A1P2RX7SMN1; SMN2KMT2AGLA | |
| SCHEMBL14277228 | 0.80 | MEN1 (0.50) | ALDH1A1P2RX7KMT2AMEN1TSHR | |
| SCHEMBL1677987 | 0.79 | ALDH1A1 (1.00) | ALDH1A1P2RX7SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL23220348 | 0.79 | ALDH1A1 (1.00) | ALDH1A1P2RX7SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL26334226 | 0.79 | ALDH1A1 (0.66) | ALDH1A1P2RX7SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL18250772 | 0.78 | ALDH1A1 (1.00) | ALDH1A1P2RX7SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30927843 | 0.77 | ALDH1A1 (0.66) | ALDH1A1P2RX7SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6270532 | 0.77 | ALDH1A1 (0.72) | ALDH1A1P2RX7SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL17993529 | 0.77 | ALDH1A1 (0.59) | ALDH1A1P2RX7SMN1; SMN2KMT2AGLA | |
| SCHEMBL19966024 | 0.77 | EPHX2 (0.77) | ALDH1A1SMN1; SMN2KMT2AMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1474139-B1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO INC (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1474139-A4 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1474139-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | Merck & Co., Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003065983-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0002066-B1 | 2-ADAMANTYL HYDRAZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Teva Pharmaceutical Industries Limited (IL) | 1983-05-25 | — | — | EP | disclosed |
| US-4254128-A | 2-Adamantyl hydrazines and biocidal compositions thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1981-03-03 | — | — | US | disclosed |
| EP-0002066-A1 | 2-Adamantyl hydrazines and pharmaceutical compositions containing them | Teva Pharmaceutical Industries Limited (IL) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD17B1, HSD11B2 | ALDH1A1 688/4885P2RX7 4725/4885SMN1; SMN2 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.